Antibody–drug conjugates have emerged as a powerful tool to deliver highly targeted cancer therapies. Next-generation antibody-drug conjugate designs aim to push the envelope even further.

Cancer treatment has entered a revolutionary phase with advancements in immunotherapy, a field that employs the immune system ...

Highlighted by Genentech's recent US regulatory submission for trastuzumab–DM1, antibody–drug conjugation technology could be heading for the mainstream in anticancer drug development.

Antibody-drug conjugates (ADCs) are at the forefront of cancer therapy, combining targeted precision with potent cytotoxicity. Conceived by Paul Ehrlich in the early 1900s, the concept of a magic ...

As pharmaceutical companies embrace antibody-drug conjugates (ADCs) as a way to treat cancer, drug services providers are investing in capacity to meet the companies’ manufacturing needs.

Antibody-drug conjugates have emerged as one of the most popular treatment modalities for investment in recent years. Following Pfizer’s proposed move for Seagen, Ben Hargreaves tracked how the ...

The Trojan horse All three of the studies Verma mentioned involved antibody-drug conjugates (ADCs), a treatment modality that’s now about a decade old but still ripe for innovation.

Researchers from Anaveon AG and affiliated organizations presented the discovery and preclinical characterization of ANV-700, a novel proximity-activated cytokine (PAC) compound designed to ...

DUBLIN--(BUSINESS WIRE)--The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.

Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics. But their complex structure poses significant development and safety challenges for biopharma. In this GEN ...

CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engagers, and immune modulators ...